Immunotherapy biomarkers and predictors of anti-checkpoint therapy success in colorectal cancer IMPACT-CRC aims to address the objectives of the EP PerMed call by leveraging...

Biodiversity Genomics Europe plus (BGE+) builds on a pan-European collaboration to scale up the production and uptake of genomic evidence for taxonomy, monitoring and policy. It widens participation, standardises methods, and prepares a distributed European system for biodiversity genomics that...

Rare diseases (RDs) affect millions globally, with over 50% of cases remaining undiagnosed due to limitations in current diagnostic tools. The xPAND project seeks to address these challenges by developing innovative multi-omics approaches that integrate long-read whole-genome sequencing (LR-WGS),...

STAMP-IT develops a novel precision oncology approach that transforms circulating immune cells into living biomarkers to predict patient responses to immune checkpoint inhibitor (ICI) therapies. Current biomarkers, such as tumor mutational burden and PD-L1 expression, have limited predictive...

Breast cancer is the most frequently diagnosed cancer in women, with European countries having some of the highest age-standardized incident rates of early-onset (< age 50) breast cancer in the world. Yet, our understanding of the genetic and environmental factors triggering the pathophysiology...

The objective of IMPaCT-Genómica 2 is to improve equitable access to faster and more reliable diagnoses for rare diseases (RDs) and low-frequency genetic tumors within the National Health System (SNS), facilitating their prevention, therapy research, and impact assessment. Previous results from...